Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial.

Hiromi MatsumotoNobuaki KobayashKohei SomekawaNobuhiko FukudaAyami KanekoChisato KamimakiSousuke KuboKatsushi TanakaYoichi TagamiShuhei TeranishiKeisuke Watanabe Nobuyuki Horita Yu Hara Masaki YamamotoMakoto KudoHarumi KoizumiKenji MiuraNaoki MiyazawaTakeshi Kaneko

Published in: Thoracic cancer (2021)

Although the PFS, OS, and RR were not significantly different between patients treated with pembrolizumab alone and or with pembrolizumab in combination with chemotherapy, patients with NSCLC having metastases to specific sites may benefit more from monotherapy.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
locally advanced
combination therapy
small cell lung cancer
open label
clinical trial
study protocol
phase iii
randomized controlled trial
squamous cell carcinoma
rectal cancer
double blind